Formulations

Standard Strength: 5 mg BPC-157 + 5 mg TB-500 (10 mg total)

Advanced Strength: 10 mg BPC-157 + 10 mg TB-500 (20 mg total)

Oral Backbone: RECOVER™ — 500 mcg BPC-157 + 2 mg GHK-Cu + 500 mg carnosine staged-release capsule, 1 cap AM, 5 days on / 2 days off

1. Clinical Overview

BPC-157 (Body Protection Compound-157)

Cytoprotective gastric pentadecapeptide. Potent angiogenic, endothelial-protective, GI-healing, and tendon/ligament-restorative peptide.

TB-500 (Thymosin Beta-4 Fragment)

Synthetic Tβ4 fragment. Dominant in actin cytoskeleton regulation, cell migration, angiogenesis, and wound repair.

The Wolverine Blend creates a single injectable, stacked regenerative platform combining BPC-157’s GI/endothelial/tendon repair with TB-500’s actin-mediated cell migration and robust angiogenesis.

2. Mechanisms & Synergy

2.1 BPC-157 Mechanisms

Angiogenesis/microvascular repair, fibroblast activation/collagen I synthesis, GI mucosal healing/barrier integrity, neuroprotective/endothelial modulation (NO/eNOS pathways).

2.2 TB-500 Mechanisms

Actin sequestration/G-actin binding/cell migration (keratinocytes, fibroblasts, myocytes), VEGF-driven angiogenesis, anti-inflammatory/anti-fibrotic (TNF-α, IL-6, neutrophil infiltration), tissue remodeling/collagen organization.

2.3 Synergy Model

Domain	BPC-157	TB-500	Synergistic Result
Angiogenesis	Organized microvascular	VEGF-driven vessels	Robust ordered re-perfusion
Actin/Migration	Fibroblast support	Direct G-actin	High-velocity tissue repopulation
Tendon/Ligament	Tendon-to-bone, collagen I	Collagen alignment, ↓adhesion	Stronger organized repair
GI/Endothelial	Strong	Weak–moderate	Systemic protection during loading
Inflammation	Anti-inflammatory/NO	Anti-inflammatory/anti-fibrotic	Lower chronic burden, better scars
Neurovascular	Neuroprotection, stability	Emerging neuroregenerative	Neuroinflammatory support

3. Clinical Applications

3.1 Musculoskeletal

Tendon/ligament healing, muscle/myofascial repair, improved tensile strength/collagen alignment, reduced recovery times.

3.2 Wound Healing & Aesthetic

Accelerated dermal closure, enhanced keratinocyte/fibroblast migration, improved scar quality, synergy with GHK-Cu, PRP/PRF, energy-based procedures.

3.3 GI / Endothelial / Systemic

BPC-157 GI/endothelial protection for patients on NSAIDs or under orthopedic stress. TB-500 vascular remodeling and anti-fibrotic actions.

4. Product Specifications

Standard Vial: 5 mg BPC-157 + 5 mg TB-500 = 10 mg total
Advanced Vial: 10 mg BPC-157 + 10 mg TB-500 = 20 mg total
Routes: Peri-tendinous/peri-ligamentous, SC/IM systemic, mesotherapy dermal grids
RECOVER™ Oral: 500 mcg BPC-157 + 2 mg GHK-Cu + 500 mg carnosine, 1 cap AM, 5/2 cycle

5. Reconstitution & Dosing

Standard Strength (5 mg + 5 mg = 10 mg)

Option	Diluent	Concentration	Use
A — High	2 mL BS	5 mg/mL total (2.5/2.5)	Focal tendon/ligament
B — Moderate	5 mL BS	2 mg/mL total (1/1)	Mesotherapy, larger fields
C — Low	10 mL BS	1 mg/mL total (0.5/0.5)	Wide dermal, sensitive pts

Advanced Strength (10 mg + 10 mg = 20 mg)

Option	Diluent	Concentration	Use
A — High	2 mL BS	10 mg/mL total (5/5)	Experienced injectors, large athletes
B — Moderate	5 mL BS	4 mg/mL total (2/2)	Standard clinical
C — Conservative	10 mL BS	2 mg/mL total (1/1)	Older/comorbid, multi-site

Per Session: Mild/focal 0.5–2 mg • Moderate 2–4 mg • Severe/multi-site 4–6+ mg
Frequency: 1×/wk or q5–7 days × 4–6 weeks. Athletes: 2×/wk lower dose
Maintenance: q2–4 weeks as needed

6. Route Selection & Injection Strategies

SC: Systemic + regional, generalized inflammation/recovery
Peri-tendinous/Peri-ligamentous: Fan/ring around injured structure (avoid intra-tendinous)
IM: Deep muscle injuries, lower volume
Mesotherapy: Dermal grids for scars, aesthetic, superficial soft-tissue

Example Injection Patterns

A. Peri-Tendinous (Achilles, patellar, lateral epicondyle)

2–4 mg/mL, 0.1–0.3 mL/site, 3–6 sites, 1–4 mg/session, q7d × 4–6 wk

B. Peri-Ligamentous (MCL, LCL, ATFL)

0.1–0.2 mL/site linear/fan, 1–3 mg/session, q5–7d × 3–4 wk

C. Mesotherapy/Scar Field

1–2 mg/mL, 1–3 mm depth, 1–1.5 cm grid, 0.5–2 mg/session, weekly × 3–6

D. SC Microdosing (Systemic)

0.25–0.5 mg SC, daily–3×/wk × 2–4 wk. Multi-site overuse, heavy training.

Peptide Protocol Portal does not recommend intra-articular injection of BPC-157 or TB-500.

7. Oral Integration — RECOVER™

Dose: 1 cap AM empty stomach, 5 on/2 off, 8–12 weeks
Why pair: GI protection (NSAID users), systemic angiogenic/endothelial support parallel to injections, GHK-Cu reinforces dermal/ECM remodeling
Moderate injury: RECOVER™ + Wolverine q7d × 4–6 wk
High-output: RECOVER™ + Wolverine weekly + optional REVIVE™ (mito) / REBALANCE™ (sleep/ANS)

8. Clinical Decision Trees

Tree 1 — Is Wolverine Blend Appropriate?

Structural soft-tissue lesion? → YES → continue

Failed conservative care? → YES → injectable Wolverine

No failure yet? → RECOVER™ ± topical first

Rapid recovery needed (athlete/occupation)? → Wolverine + RECOVER™ + PT/PRP

Contraindications? → Avoid/modify/refer

Tree 2 — Route & Dose

Localization: Focal tendon/ligament → Peri-tendinous • Diffuse muscle/fascia → SC/IM + meso • Dermal/scar → Mesotherapy • Systemic/multi-site → SC micro + RECOVER™

Severity: Mild → RECOVER™ ± low-dose SC • Moderate → RECOVER™ + targeted 1–3 mg • Severe → RECOVER™ + 3–6 mg + PRP/shockwave/PT

Patient: Older/comorbid → lower conc, slower titration • High-output athlete → more aggressive, close monitoring

Flowchart — Musculoskeletal Protocol Builder

Tendon: Acute <3 mo → RECOVER™ + Wolverine q7d × 3–4. Chronic >3 mo → q7d × 4–6 + PT + PRP

Ligament: Grade I–II → RECOVER™ + brace + Wolverine q7d × 3–4. Grade III → surgical eval ± peri-op support

Muscle/Fascia: Partial → RECOVER™ + SC/IM Wolverine ± mesotherapy. Large tear → imaging + surgical consult, Wolverine adjunct only

9. Clinical Archetypes

A — Chronic Tendinopathy (Lateral Epicondylitis)

RECOVER™ 1 cap AM 5/2 × 12 wk + Wolverine Standard 2 mg/session (0.2 mL × 5 sites), q7–10d × 4–6. Adjunctive: eccentric training, bracing, shockwave/PRP.

B — Acute Grade II MCL Sprain (Athletic)

RECOVER™ × 8–12 wk + Wolverine 3–4 mg/session, fan along MCL, 6–8 sites, q7d × 3–4. Hinged brace, PT, return-to-play testing.

C — Post-Op Soft-Tissue Repair (Rotator Cuff)

RECOVER™ once oral tolerated × 12 wk + Wolverine 2–3 mg around tendon footprint, q7–14d × 3–4 (surgeon-approved). PT, PRP, biologics.

D — Aesthetic Multi-Modality (Face/Neck)

RECOVER™ × 8–12 wk + Wolverine meso 0.5–1.5 mg intradermal grid, q2–4 wk × 3–4. GHK-Cu topical, PRiVIVE™, RF/microneedling/laser.

E — High-Output Athlete, Multi-Site Overuse

RECOVER™ + optional REVIVE™/REBALANCE™ + SC micro 0.5–1 mg q48h × 2–4 wk + targeted peri-tendinous 2–3 mg weekly. Load management, nutrition, sleep.

10. Safety & Contraindications

Absolute

Pregnancy / Lactation
Known hypersensitivity
Inability to provide informed consent

Relative

Active malignancy (angiogenesis-modulating)
Severe hepatic disease / organ failure
Coagulation disorders / potent anticoagulants (injectables)
Active infection at/near injection site
Pediatric (insufficient data)

Monitoring

Subjective: Pain scores, functional scales, recovery time, GI tolerance. Objective: Ultrasound/MRI follow-up, ROM/strength, CRP/ESR, LFTs in high-risk.

Adverse Effects

Typically mild: injection-site erythema/discomfort, transient fatigue/headache, local edema if dose/volume excessive.

Legal Disclaimer

This document is provided solely for educational and informational purposes. BPC-157, TB-500, and Wolverine Blend are not FDA-approved drugs. Peptide Protocol Portal makes no representations or warranties. By using this document, the reader agrees that Peptide Protocol Portal shall not be held liable. Use at your own risk.

References — Wolverine Blend

BPC-157 — Angiogenesis, Soft-Tissue, Cytoprotection

1. Sikiric, P., et al. Multi-system BPC-157 review. Curr Pharm Des, 24(19), 2182–2200 (2018).

2. Sikiric, P., et al. Angiogenesis/cytoprotection. J Physiol, 596(6), 965–982 (2018).

3. Staresinic, M., et al. Wound healing/adhesion reduction. Dig Dis Sci, 48(10), 2072–2080 (2003).

4. Seiwerth, S., et al. Tendon/ligament healing. J Orthop Res, 32(5), 683–691 (2014).

5. Novak, M., et al. Multi-tissue regeneration. Acta Orthop Belg, 66(1), 53–60 (2000).

6. Gojkovic, S., et al. NSAID-induced GI protection. Life Sci, 173, 32–40 (2017).

7. Sikiric, P., et al. GI barrier/systemic inflammation. Inflamm Res, 59(11), 921–930 (2010).

8. Seiwerth, S., et al. Endothelial/microvascular stability. Vascul Pharmacol, 102, 1–9 (2018).

9. Jelovac, T., et al. TBI/peripheral nerve healing. Neurosci Lett, 587, 13–18 (2015).

10. Vukojević, J., et al. Multi-tissue repair review. Int J Mol Sci, 20(19), 4957 (2019).

TB-500 — Actin, Migration, Angiogenesis, Anti-Fibrotic

11. Low, T. L. K., & Goldstein, A. L. Tβ4 discovery. PNAS, 72(1), 200–204 (1975).

12. Huff, T., et al. Tβ4 structure/function. Ann NY Acad Sci, 1112, 402–414 (2007).

13. Safer, D., et al. Actin/cytoskeletal dynamics. PNAS, 88(14), 6608–6612 (1991).

14. Sosne, G., et al. Tβ4 healing fragments. J Biol Chem, 279(7), 5389–5396 (2004).

15. Smart, N., et al. Tissue regeneration landmark. Nature, 474(7351), 444–448 (2011).

16. Malinda, K. M., et al. Re-epithelialization/keratinocyte. J Invest Dermatol, 113(1), 112–120 (1999).

17. Sosne, G., et al. Anti-inflammatory/reparative. Invest Ophthalmol Vis Sci, 43(3), 756–762 (2002).

18. Yang, H., et al. TGF-β fibrosis suppression. Cell Physiol Biochem, 31(1), 67–78 (2013).

19. Bock-Moloney, M. C., et al. Preclinical safety Tβ4. Toxicol Pathol, 39(7), 1101–1112 (2011).

Wolverine Blend (BPC-157 + TB-500)